ERLEADA™ (apalutamide)

As soon as you see a rapidly rising PSA in patients receiving ADT...

Push Back
on Progression

For Patients with Non-Metastatic CRPC

  • On ADT

  • With a rapidly rising PSA*

  • And no radiographically detectable metastases

In the SPARTAN study:

ERLEADA + ADT improved median metastasis-free survival (MFS) by 2 YEARS (24.3 months) vs placebo + ADT1

(40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)

Review the SPARTAN Publication

Learn more about the results of the SPARTAN study in "Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer" published in the New England Journal of Medicine.

This article may only be available to subscribers of the New England Journal of Medicine (NEJM). To access this content, you may have to sign in using your personal or institutional credentials. If you are not registered or a member of NEJM, then you may need to purchase this article through their site.


Your One Source for Access, Affordability, and Treatment Support for Your Patients

Call a Janssen Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8 AM to 8 PM ET.

Download a list of specialty pharmacies that distribute ERLEADA™.

*PSA doubling time <10 months.

ADT = androgen-deprivation therapy; CRPC = castration-resistant prostate cancer; HR = hazard ratio; PSA = prostate-specific antigen; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509.

Reference: 1. ERLEADATM [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.